Latest Cost Management News

DGL Group Limited reported a 3% revenue increase to $481.5 million for FY25 but swung to a $24.6 million net loss driven by asset impairments and operational challenges. The company is undertaking significant restructuring and integration efforts to restore profitability.

Jayride Group Limited revealed a 55.5% plunge in revenue to $2.42 million for the fiscal year ending June 2025, alongside a reduced net loss of $5.7 million, signaling some financial stabilization despite ongoing challenges.

Constellation Technologies Limited has reported a 34% revenue increase and a return to profitability in FY25, driven by strong adoption of its IoT-based food safety solutions across multiple sectors. The company is scaling its innovative Callisto platform and hardware offerings to capture broader market opportunities.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Dubber Corporation Limited reported a 9% increase in revenue to $42.19 million for FY25, alongside a significant reduction in net loss. However, challenges remain with a major contract non-renewal and ongoing efforts to recover $26.6 million in misused funds.

Cluey Ltd reported a 50% improvement in EBITDA and its first positive operating cash flow quarter in FY25, driven by cost efficiencies and a return to student growth. The company is now pivoting towards AI-enabled product innovation to fuel sustainable expansion.

Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.

K2 Asset Management posted a 17% revenue increase and returned to profitability in FY25, declaring a fully franked dividend and signalling plans for mergers and acquisitions to accelerate expansion.

K2 Asset Management Holdings Ltd has reported a strong financial year ending June 2025, with revenues up 17% and a return to profitability, alongside a fully franked dividend declaration.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.